Public Staff Retirement System of Ohio acquired a brand new stake in Anika Therapeutics, Inc. (NASDAQ:ANIK – Free Report) within the 4th quarter, based on the corporate in its most up-to-date 13F submitting with the SEC. The agency acquired 8,319 shares of the biotechnology firm’s inventory, valued at roughly $137,000. Public Staff Retirement System of Ohio owned roughly 0.06% of Anika Therapeutics on the finish of the latest reporting interval.
A number of different giant traders have additionally not too long ago purchased and bought shares of the inventory. Aquatic Capital Administration LLC acquired a brand new place in Anika Therapeutics through the fourth quarter price $42,000. Tower Analysis Capital LLC TRC grew its place in shares of Anika Therapeutics by 412.4% within the 4th quarter. Tower Analysis Capital LLC TRC now owns 2,890 shares of the biotechnology firm’s inventory valued at $48,000 after buying an extra 2,326 shares through the interval. Wells Fargo & Firm MN elevated its stake in shares of Anika Therapeutics by 31.1% through the 4th quarter. Wells Fargo & Firm MN now owns 7,421 shares of the biotechnology firm’s inventory price $122,000 after buying an extra 1,759 shares over the last quarter. Connors Investor Companies Inc. elevated its stake in shares of Anika Therapeutics by 8.0% through the 4th quarter. Connors Investor Companies Inc. now owns 11,560 shares of the biotechnology firm’s inventory price $190,000 after buying an extra 861 shares over the last quarter. Lastly, Los Angeles Capital Administration LLC raised its holdings in shares of Anika Therapeutics by 9.1% within the 4th quarter. Los Angeles Capital Administration LLC now owns 11,700 shares of the biotechnology firm’s inventory valued at $193,000 after buying an extra 980 shares through the interval. 91.53% of the inventory is owned by institutional traders and hedge funds.
Analysts Set New Value Targets
Numerous equities analysts not too long ago commented on the corporate. Barrington Analysis lowered their value goal on Anika Therapeutics from $20.00 to $19.00 and set an “outperform” ranking for the corporate in a report on Monday, Might twelfth. B. Riley started protection on Anika Therapeutics in a analysis be aware on Thursday, April seventeenth. They set a “purchase” ranking and a $21.00 goal value for the corporate. Lastly, Wall Avenue Zen lowered Anika Therapeutics from a “purchase” ranking to a “maintain” ranking in a report on Monday, Might twelfth.
Get Our Newest Report on Anika Therapeutics
Anika Therapeutics Inventory Efficiency
Shares of ANIK opened at $11.19 on Friday. The agency has a market cap of $160.48 million, a P/E ratio of -1.68 and a beta of 0.66. Anika Therapeutics, Inc. has a 52 week low of $10.89 and a 52 week excessive of $29.12. The agency’s 50-day easy shifting common is $13.15 and its 200 day easy shifting common is $15.52.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) final launched its quarterly earnings outcomes on Wednesday, March twelfth. The biotechnology firm reported ($0.14) earnings per share for the quarter, lacking the consensus estimate of ($0.01) by ($0.13). The agency had income of $30.60 million for the quarter, in comparison with analyst estimates of $29.00 million. Anika Therapeutics had a damaging return on fairness of two.22% and a damaging web margin of 59.40%. As a gaggle, equities analysts forecast that Anika Therapeutics, Inc. will publish -0.84 earnings per share for the present yr.
Anika Therapeutics Firm Profile
(Free Report)
Anika Therapeutics, Inc, a joint preservation firm, creates and delivers developments in early intervention orthopedic care within the areas of osteoarthritis (OA) ache administration, regenerative options, sports activities drugs, and arthrosurface joint options in america, Europe, and internationally.
Featured Tales
Obtain Information & Scores for Anika Therapeutics Day by day – Enter your e-mail handle under to obtain a concise every day abstract of the newest information and analysts’ scores for Anika Therapeutics and associated corporations with MarketBeat.com’s FREE every day e-mail publication.
